Ken Griffin Coherus Bio Sciences, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.99 - $1.8 $1,386 - $2,520	-1,400 Reduced 4.56%	29,300 $30,000
Q2 2024 Aug 14, 2024	SELL	$1.58 - $2.51 $13,430 - $21,335	-8,500 Reduced 21.68%	30,700 $53,000
Q1 2024 May 15, 2024	SELL	$2.02 - $3.14 $40,602 - $63,114	-20,100 Reduced 33.9%	39,200 $93,000
Q4 2023 Feb 14, 2024	BUY	$1.59 - $3.85 $68,688 - $166,320	43,200 Added 268.32%	59,300 $197,000
Q3 2023 Nov 14, 2023	SELL	$3.74 - $5.45 $87,142 - $126,985	-23,300 Reduced 59.14%	16,100 $60,000
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $30,320 - $66,400	8,000 Added 25.48%	39,400 $168,000
Q1 2023 May 15, 2023	SELL	$5.89 - $10.52 $17,081 - $30,508	-2,900 Reduced 8.45%	31,400 $214,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $195,167 - $345,401	34,300 New	34,300 $271,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $114M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.